Why are the First-Line Therapies Used as Injections Discontinued in the Treatment of Multiple Sclerosis?

Authors : Sedat ŞEN, Murat TERZİ

Pages : 7-13

Doi:10.56484/iamr.1087921

View : 14 | Download : 10

Publication Date : 2022-06-30

Article Type : Research Paper

Abstract :Objective: Immunomodulatory therapies insert ignore into journalissuearticles values(IMTs); are used in the treatment of multiple sclerosis insert ignore into journalissuearticles values(MS); considering their efficacy and safety. Although other effective treatments have been used in recent years, the use of IMTs still continues. In this study, we aimed to reveal the reasons for the discontinuation of IMTs used as injections. Method: IMTs data of 1464 patients were collected and analysed from the Imed database, where 20-year data of the patients were entered by us. Groups were divided as; Interferon beta-1a subcutaneous insert ignore into journalissuearticles values(IFN-β1a SC);, Interferon beta-1a intramuscular insert ignore into journalissuearticles values(IFN-β1a IM);, glatiramer acetate insert ignore into journalissuearticles values(GA); and Interferon beta-1b insert ignore into journalissuearticles values(IFN-β1b);. Age, gender, duration of illness, types of disease onset, time to start the injection, duration of injection therapy, and reason for discontinuation of patients were analysed. Results: The most common reason for discontinuation of treatments was found to be disease progression insert ignore into journalissuearticles values(20.13%, 28.14%, 19.64%, 23.87%);. Side effects, increased attack frequency, patient demand, disease activity detection in imaging methods, and pregnancy planning followed the disease progression respectively. Conclusion: IMTs as an injection form are used in the treatment of MS, considering their effectiveness and reliability. The most common reason for discontinuing treatment is disease progression.
Keywords : Multiple sclerosis, immunomodulatory therapy, interferon beta, glatiramer acetate